INmune Bio, Inc. (NASDAQ:INMB) Stake Lessened by Janney Montgomery Scott LLC

Janney Montgomery Scott LLC cut its stake in INmune Bio, Inc. (NASDAQ:INMB) by 36.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 163,559 shares of the company’s stock after selling 93,328 shares during the period. Janney Montgomery Scott LLC owned approximately 0.91% of INmune Bio worth $1,842,000 at the end of the most recent reporting period.

Separately, Bank of New York Mellon Corp bought a new position in shares of INmune Bio in the third quarter valued at approximately $223,000. Institutional investors and hedge funds own 12.72% of the company’s stock.

INmune Bio Stock Performance

Shares of NASDAQ:INMB opened at $10.11 on Monday. The stock has a market capitalization of $199.98 million, a price-to-earnings ratio of -5.27 and a beta of 1.92. INmune Bio, Inc. has a 1-year low of $6.50 and a 1-year high of $14.74. The company has a 50 day moving average price of $10.77 and a 200 day moving average price of $10.98.

INmune Bio (NASDAQ:INMB) last issued its earnings results on Thursday, May 9th. The company reported ($0.61) earnings per share for the quarter. The business had revenue of $0.01 million for the quarter. INmune Bio had a negative return on equity of 86.16% and a negative net margin of 26,333.59%.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.